Skip to main content
Clinical Trials/NCT05640947
NCT05640947
Recruiting
Not Applicable

Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass: a Proof of Concent Study

University Hospital, Ghent2 sites in 1 country20 target enrollmentJanuary 30, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypoglycemia
Sponsor
University Hospital, Ghent
Enrollment
20
Locations
2
Primary Endpoint
clinical succes rate
Status
Recruiting
Last Updated
6 months ago

Overview

Brief Summary

The primary objective of this open-label pilot study is to investigate whether an endoscopically placed lumen apposing metal stent is an effective alternative to surgery in patients that have a clear indication for reversal of their gastric bypass.

Registry
clinicaltrials.gov
Start Date
January 30, 2023
End Date
February 1, 2028
Last Updated
6 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Group 1) patients needing any kind of parenteral nutritional support (eg. hypo- albuminemia, hypovitaminoses, mineral deficiencies,...) that can not be corrected by dietary intervention/oral supplementation
  • Group 2) patients with persistent invalidating symptomatic dumping syndrome despite optimal dietary intervention (typical complaints are headache, sweating, trembling, weakness and feeling hungry).
  • Group 3) patients with a refractory marginal ulcers with stenosis of the gastrojejunostomy leading to feading difficulties.
  • Group 4) patients with F3 or F4 liver fibrosis and a tendency to decompensation after bypass surgery, as demonstrated by an increase in serum bilirubin/INR and/or lowering of serum albumin.

Exclusion Criteria

  • Uncorrectable coagulopathy
  • Presence of significant portal hypertension as demonstrated by 2.1) the presence of esophageal and/or gastric varices AND/OR 2.2) a hepatic venous pressure gradient (if measured) equal to or more than 10mm Hg AND/OR 2.3) the combination of
  • a platelet count \<150000/µl AND
  • liver stiffness measured by elastometry equal to or more than 20 kPa (Baveno guidelines).
  • Pregnant women, breastfeeding women or women that can not assure adequate anticonception for the duration of the study (based on anamnesis).
  • Karnofsky index less than 60
  • Vulnerable patients

Outcomes

Primary Outcomes

clinical succes rate

Time Frame: 6 months

1. for patients needing parenteral support: the number of parenteral supplements over a 6-month timeframe. 2. for patients with symptomatic hypoglycemia: resolution of hypoglycemia- associated complaints + negative hypoglycemia-provocative testing (oral glucose tolerance test and/or mixed meal test) at 6 months post-intervention. 3. for patients with gastric outlet obstruction: resolution of gastric outlet obstruction- associated symptoms at 6 months post-intervention. 4. for patients with steatohepatitis and signs of liver failure: improvement of liver function (significant drop in bilirubin/INR; increase in serum albumin) at 6 months post-intervention.

Secondary Outcomes

  • Technical success rate(12 months)
  • Duration of the procedure(12 months)
  • Complication rate(12 months)
  • Reintervention rate(12 months)

Study Sites (2)

Loading locations...

Similar Trials